ArticleJournal of neuro-oncology2020
Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.
Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review.Current oncology (Toronto, Ont.) · 2024Pooled it
- Use of 18F-FDG-PET/CT in differential diagnosis of primary central nervous system lymphoma and high-grade gliomas: A meta-analysis.Frontiers in neurology · 2022Pooled it
- Can baseline 18F-FDG PET/CT predict the prognosis of primary CNS lymphoma?Neuro-oncology · 2025Article
- The Prognostic Significance of Pontine-White Matter Score in Primary Central Nervous System Lymphoma Patients.Cancers · 2024Article
- Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era.Annals of hematology · 2023Article
- Primary central nervous system lymphoma.Nature reviews. Disease primers · 2023Review
- Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.Annals of hematology · 2023Article
- Effect of steroid treatment on the diagnostic yield of baselineEJNMMI research · 2022Article
- Review
- Review
- An Update on Neurosurgical Management of Primary CNS Lymphoma in Immunocompetent Patients.Frontiers in oncology · 2022Review
- Reply to letter to the editor by Gupta et al: Bone marrow biopsy in patients with PCNSL: relevant or redundant?Neuro-oncology · 2021Article
- The value of bone marrow biopsy for staging of patients with primary CNS lymphoma.Neuro-oncology · 2021Article
- Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma.Oncology letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary Central Nervous System Lymphoma (PCNSL) is a rare disease with different therapeutic implications than systemic lymphoma. In this study, we evaluated whole-body
methodsOne hundred and thirty consecutive immunocompetent patients were retrospectively included. The results of initial
resultsCNS lesion pathology showed large B-cell lymphoma in 95% of patients, including 11 patients with primary vitro-retinal lymphoma. Ten patients (8%) where ultimately diagnosed with systemic lymphoma involvement, including five pathologically confirmed cases, all of which were detected by
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.